CL2019003708A1 - Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas. - Google Patents
Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas.Info
- Publication number
- CL2019003708A1 CL2019003708A1 CL2019003708A CL2019003708A CL2019003708A1 CL 2019003708 A1 CL2019003708 A1 CL 2019003708A1 CL 2019003708 A CL2019003708 A CL 2019003708A CL 2019003708 A CL2019003708 A CL 2019003708A CL 2019003708 A1 CL2019003708 A1 CL 2019003708A1
- Authority
- CL
- Chile
- Prior art keywords
- mitoketoskines
- mitochondria
- cancer cells
- therapeutic agents
- compounds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000002576 ketones Chemical class 0.000 title 1
- 230000004060 metabolic process Effects 0.000 title 1
- 210000003470 mitochondria Anatomy 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002438 mitochondrial effect Effects 0.000 abstract 2
- 230000002407 ATP formation Effects 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 101000598552 Homo sapiens Acetyl-CoA acetyltransferase, mitochondrial Proteins 0.000 abstract 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 abstract 1
- 101000716763 Homo sapiens Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Proteins 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 abstract 1
- 102100020868 Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial Human genes 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/14—Libraries containing macromolecular compounds and not covered by groups C40B40/06 - C40B40/12
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA PRESENTE DESCRIPCIÓN SE REFIERE A COMPUESTOS QUE SE ENLAZAN A POR LO MENOS UNA DE ACAT1/2 Y OXCT1/2 E INHIBEN LA PRODUCCIÓN MITOCONDRIAL DE ATP, REFERIDOS EN ESTE DOCUMENTO COMO MITOCETOSCINAS. SE DAN A CONOCER MÉTODOS DE PROSPECCIÓN DE COMPUESTOS POR LA INHIBICIÓN MITOCONDRIAL Y PROPIEDADES ANTICANCEROSAS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR MITOCETOSCINAS PARA PREVENIR O TRATAR CÁNCER, INFECCIONES BACTERIANAS Y LEVADURA PATÓGENA, ASÍ COMO TAMBIÉN MÉTODOS PARA USAR MITOCETOSCINAS PARA PROPORCIONAR BENEFICIOS ANTIENVEJECIMIENTO. TAMBIÉN SE DAN A CONOCER COMPUESTOS DE MITOCETOSCINA ESPECÍFICOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524829P | 2017-06-26 | 2017-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003708A1 true CL2019003708A1 (es) | 2020-05-15 |
Family
ID=64742979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003708A CL2019003708A1 (es) | 2017-06-26 | 2019-12-17 | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11667639B2 (es) |
| EP (1) | EP3644988B1 (es) |
| JP (1) | JP7397672B2 (es) |
| KR (2) | KR20240038805A (es) |
| CN (1) | CN110913854B (es) |
| AU (2) | AU2018292283B2 (es) |
| BR (1) | BR112019026097A2 (es) |
| CA (1) | CA3064452A1 (es) |
| CL (1) | CL2019003708A1 (es) |
| CO (1) | CO2019014259A2 (es) |
| CR (1) | CR20200033A (es) |
| CU (1) | CU20190106A7 (es) |
| DO (2) | DOP2019000312A (es) |
| EC (1) | ECSP20001729A (es) |
| IL (2) | IL292109B2 (es) |
| MX (1) | MX2019014806A (es) |
| PE (1) | PE20200295A1 (es) |
| PH (1) | PH12019502892A1 (es) |
| RU (1) | RU2020102908A (es) |
| SG (1) | SG11201913134UA (es) |
| WO (1) | WO2019005698A1 (es) |
| ZA (2) | ZA201907831B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078791A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | Anti-mitochondrial inhibitors for oncogenic ras and myc |
| JP2021501774A (ja) * | 2017-11-03 | 2021-01-21 | バイオイミクス・アクチボラグＢｉｏｉｍｉｃｓ ＡＢ | 抗感染症複素環式化合物及びその使用 |
| CR20210221A (es) | 2018-10-02 | 2021-06-24 | Lunella Biotech Inc | Derivados de azitromicina y roxitromicina como fármacos senolíticos |
| EP3976197A4 (en) | 2019-05-24 | 2023-07-19 | Lunella Biotech, Inc. | THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
| EP0310361A3 (en) | 1987-09-30 | 1989-05-24 | Beckman Instruments, Inc. | Tridentate conjugate and method of use thereof |
| SI9011409A (en) | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
| FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
| EP0656422B1 (en) | 1993-11-05 | 2000-04-26 | Amersham Pharmacia Biotech UK Limited | Chloramphenicol acetyl transferase (CAT) assay |
| WO1995015770A1 (en) | 1993-12-09 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
| US5441939A (en) | 1994-03-04 | 1995-08-15 | Pfizer Inc. | 3"-desmethoxy derivatives of erythromycin and azithromycin |
| US5795871A (en) | 1994-04-26 | 1998-08-18 | Nobuhiro Narita | Pharmaceutical composition for treatment of non-small cell lung cancer |
| AU693013B2 (en) | 1995-05-03 | 1998-06-18 | Pfizer Inc. | Novel tetracycline derivatives |
| JP4590523B2 (ja) | 1997-11-25 | 2010-12-01 | アンティポディーン ファーマシューティカルズ インコーポレイテッド | ミトコンドリアを標的とする抗酸化剤 |
| DE69919769T2 (de) | 1998-03-03 | 2005-01-27 | Pfizer Products Inc., Groton | 3,6-Ketal-Makrolidantibiotika |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
| WO2004069159A2 (en) | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| TWI324600B (en) | 2003-07-07 | 2010-05-11 | Kowa Co | 2,4-bis (trifluoroethoxy) pyridine compound and drug containing the compound |
| US20070105937A1 (en) | 2003-12-22 | 2007-05-10 | Miguel Pappolla | Indole-3-propionamide and derivatives thereof |
| US20050256081A1 (en) | 2004-02-26 | 2005-11-17 | Peyman Gholam A | Tetracycline derivatives for the treatment of ocular pathologies |
| US20060083727A1 (en) | 2004-07-15 | 2006-04-20 | Nanobac Pharmaceuticals, Inc. | Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| JP5065910B2 (ja) | 2005-01-14 | 2012-11-07 | グラクソ グループ リミテッド | ビオチンおよび光親和性基を含む、マクロライド標的同定用のマクロライド化合物 |
| ZA200800907B (en) | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
| MX2008014953A (es) | 2006-05-26 | 2009-03-05 | Bayer Healthcare Llc | Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer. |
| US20090311249A1 (en) | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20070292906A1 (en) | 2006-06-14 | 2007-12-20 | Bristol-Myers Squibb Company | Assay for measuring acyltransferase activity |
| CN101631799A (zh) | 2006-10-30 | 2010-01-20 | 南方研究院 | 靶向nbs1-atm相互作用以使癌细胞对放射疗法及化学疗法敏感 |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| US8075902B2 (en) | 2007-01-03 | 2011-12-13 | Michael Powell | Diagnosis and treatment of cancer related to human dormancy |
| US8647673B2 (en) | 2007-07-24 | 2014-02-11 | Wayne State University | Nanoparticles for imaging and treating chlamydial infection |
| WO2009038656A1 (en) | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
| US20100285001A1 (en) | 2007-10-02 | 2010-11-11 | University Of Rochester | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations |
| SG175251A1 (en) | 2009-04-17 | 2011-11-28 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| EA201101639A1 (ru) | 2009-05-20 | 2012-06-29 | Юниверсите Де Женев | Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение |
| CN109224064A (zh) | 2009-12-04 | 2019-01-18 | 昂科免疫有限公司 | 低氧诱导因子抑制剂的用途 |
| WO2011140047A1 (en) | 2010-05-04 | 2011-11-10 | Trustees Of Dartmouth College | Methods for identifying allosteric and other novel acyl-coenzyme a:cholesterol acyltransferase inhibitors |
| EP2606349A4 (en) * | 2010-08-20 | 2014-04-30 | Univ Jefferson | AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY |
| US20120141467A1 (en) | 2010-12-03 | 2012-06-07 | Schneider Daniel J | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma |
| US20130172430A1 (en) | 2010-12-10 | 2013-07-04 | Michael P. Lisanti | Prognosis and treatment of breast cancer |
| BR112013033239A2 (pt) | 2011-06-22 | 2016-09-06 | Vyome Biosciences | pró-farmácos de conjugado baseado em atifungicos e antibacterianos |
| WO2013007708A1 (en) | 2011-07-08 | 2013-01-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for treatment of liver cancer |
| US9801922B2 (en) | 2011-08-03 | 2017-10-31 | University Of Iowa Research Foundation | Compositions and methods of treating cancer |
| WO2013024467A2 (en) | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
| KR20140072090A (ko) * | 2011-09-09 | 2014-06-12 | 뉴욕 유니버시티 | ＲＯＲγｔ 조정제로서의 아미도 화합물 및 이의 용도 |
| US9775855B2 (en) | 2011-09-14 | 2017-10-03 | Thomas J. Lewis | Compositions comprising macrolide and tetracycline and their uses |
| CA2866080C (en) | 2012-03-01 | 2021-01-19 | University Of Cincinnati | Ros-activated compounds as selective anti-cancer therapeutics |
| WO2014036037A1 (en) | 2012-08-28 | 2014-03-06 | Annam Biosciences, Llc | N-boc-dendrimers and their conjugates |
| WO2014036654A1 (en) | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
| US20140106004A1 (en) | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| US9636329B2 (en) | 2012-11-06 | 2017-05-02 | Northwestern University | Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors |
| WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| US8728546B1 (en) * | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| US10004809B2 (en) | 2013-07-01 | 2018-06-26 | University Of Georgia Research Foundation Inc. | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy |
| CA2843943A1 (en) | 2014-02-20 | 2014-05-28 | Pankaj Modi | Oral formulations of chemotherapeutic agents |
| WO2015191668A1 (en) | 2014-06-10 | 2015-12-17 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| GB201414806D0 (en) | 2014-08-20 | 2014-10-01 | Ucl Business Plc | Cyclosporin conjugates |
| WO2016059247A1 (en) | 2014-10-17 | 2016-04-21 | Targeted Therapies Research And Consulting Centre Sprl (Ttrcc) | Multi-ingredient pharmaceutical composition for use in cancer therapy |
| JP6439931B2 (ja) | 2015-02-26 | 2018-12-19 | 大日本印刷株式会社 | 吸着搬送装置および吸着搬送方法 |
| EP3359255A4 (en) | 2015-10-06 | 2019-06-12 | Redhill Biopharma Ltd. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| JP2019528689A (ja) | 2016-08-11 | 2019-10-17 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫調節化合物 |
| WO2018136617A2 (en) | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
| US20190365830A1 (en) | 2017-01-18 | 2019-12-05 | Evelo Biosciences, Inc. | Methods of treating cancer |
| WO2018195446A1 (en) | 2017-04-21 | 2018-10-25 | Lisanti Michael P | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| EP3612187B1 (en) | 2017-04-21 | 2022-04-13 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| WO2018202910A1 (en) | 2017-05-05 | 2018-11-08 | Fondazione Istituto Italiano Di Tecnologia | Combination of antibiotic and bcl-2 inhibitor and uses thereof |
| WO2018213764A1 (en) | 2017-05-19 | 2018-11-22 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| BR112019024264A2 (pt) | 2017-05-19 | 2020-06-02 | Lunella Biotech, Inc. | Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer |
| WO2018218242A1 (en) | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Methods and compositions for combination therapy |
-
2018
- 2018-06-25 MX MX2019014806A patent/MX2019014806A/es unknown
- 2018-06-25 JP JP2019570935A patent/JP7397672B2/ja active Active
- 2018-06-25 EP EP18822701.1A patent/EP3644988B1/en active Active
- 2018-06-25 CR CR20200033A patent/CR20200033A/es unknown
- 2018-06-25 PE PE2019002554A patent/PE20200295A1/es unknown
- 2018-06-25 KR KR1020247007593A patent/KR20240038805A/ko active Application Filing
- 2018-06-25 BR BR112019026097-8A patent/BR112019026097A2/pt unknown
- 2018-06-25 CU CU2019000106A patent/CU20190106A7/es unknown
- 2018-06-25 CN CN201880042546.XA patent/CN110913854B/zh active Active
- 2018-06-25 RU RU2020102908A patent/RU2020102908A/ru unknown
- 2018-06-25 CA CA3064452A patent/CA3064452A1/en active Pending
- 2018-06-25 WO PCT/US2018/039354 patent/WO2019005698A1/en active Search and Examination
- 2018-06-25 IL IL292109A patent/IL292109B2/en unknown
- 2018-06-25 KR KR1020207001405A patent/KR102646172B1/ko active IP Right Grant
- 2018-06-25 AU AU2018292283A patent/AU2018292283B2/en active Active
- 2018-06-25 US US16/626,426 patent/US11667639B2/en active Active
- 2018-06-25 SG SG11201913134UA patent/SG11201913134UA/en unknown
-
2019
- 2019-11-20 IL IL270774A patent/IL270774A/en unknown
- 2019-11-26 ZA ZA2019/07831A patent/ZA201907831B/en unknown
- 2019-12-17 CO CONC2019/0014259A patent/CO2019014259A2/es unknown
- 2019-12-17 CL CL2019003708A patent/CL2019003708A1/es unknown
- 2019-12-19 DO DO2019000312A patent/DOP2019000312A/es unknown
- 2019-12-20 PH PH12019502892A patent/PH12019502892A1/en unknown
-
2020
- 2020-01-10 EC ECSENADI20201729A patent/ECSP20001729A/es unknown
- 2020-02-27 US US16/803,628 patent/US11667640B2/en active Active
- 2020-10-23 AU AU2020257159A patent/AU2020257159B2/en active Active
-
2021
- 2021-03-24 ZA ZA2021/01954A patent/ZA202101954B/en unknown
-
2022
- 2022-07-06 DO DO2022000142A patent/DOP2022000142A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003708A1 (es) | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas. | |
| UY37145A (es) | Ligandos de direccionamiento | |
| DOP2022000165A (es) | MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS | |
| CO7461144A2 (es) | Tratamiento de una formación subterránea con una composición que incluye un microorganismo o compuesto generado por este | |
| UY37146A (es) | Ligandos de direccionamiento para compuestos terapéuticos | |
| BR112018009954A2 (pt) | materiais e métodos para o tratamento de miopatias baseadas em titinas e outras titinopatias | |
| BR112016012870A8 (pt) | composições e métodos para melhorar a produção de alface | |
| BR112016003127A2 (pt) | composições e métodos para modular rna | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| CL2020001108A1 (es) | Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial. | |
| PE20151654A1 (es) | Inhibidores de cdc7 | |
| BR112018074304A2 (pt) | composições de nanopartículas, kit e método para tratar um indivíduo com câncer resistente a fármacos | |
| BR112018017077A2 (pt) | terapias de combinação para tratamento de atrofia muscular espinhal | |
| AR103041A1 (es) | Supresión de arni parental de gen hunchback para el control de las plagas de hemípteros | |
| BR112016025791A2 (pt) | microrganismo modificado, método para produzir um composto orgânico e uso de um microrganismo modificado | |
| BR112017018861A2 (pt) | métodos para tratar câncer mantendo perda hemizigótica de tp53 | |
| AR098819A1 (es) | Método y composiciones para el control de insectos plaga en plantas por medio del silenciamiento de genes de la familia de la quitina sintasa y de la vitelogenina así como alternativamente por la expresión del gen de una toxina cry | |
| BR112016018193A2 (pt) | micro-organismo modificado, método de produção de composto orgânico e uso de micro-organismo modificado | |
| BR112019000837A2 (pt) | células miméticas de célula b | |
| BR112018071695A2 (pt) | composições e métodos para a expressão gênica acentuada de pklr | |
| AR101211A1 (es) | Composición antimicrobiana sinérgica | |
| BR112018001988A2 (pt) | métodos e composições para o controle de fungos de ferrugem através da inibição de expressão do gene hxt1 | |
| AR105031A1 (es) | Composición microbicida | |
| AR096390A1 (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |